You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARPi resistance

Showing 1 - 25 of 7,998
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 26, 2022

Epithelial Ovarian Cancer Trial in Hangzhou (Pamiparib)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 4, 2022

Breast Cancer Trial in France (Main study:, Sub-study:)

Recruiting
  • Breast Cancer
  • Main study:
  • Sub-study:
  • Bordeaux, France
  • +20 more
Jan 2, 2023

Ovarian Cancer Recurrent Trial in Sutton, London (Niraparib oral capsule, SBRT)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Niraparib oral capsule
  • SBRT
  • Sutton, Surrey, United Kingdom
  • +1 more
Aug 10, 2023

HRD and Resistance to PAPPi in EOC Patients

Recruiting
  • Epithelial Ovarian Cancer
  • +6 more
  • Testing of homologous recombination deficiency
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Efficacy and Safety Trial in Zhejiang (Arsenic trioxide Tablet +Fuzuloparib Capsules)

Recruiting
  • Efficacy and Safety
  • Arsenic trioxide Tablet +Fuzuloparib Capsules
  • Zhejiang, Hangzhou, China
    Women's Hospital School Of Medicine Zhejiang University
Jan 23, 2022

HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

Recruiting
  • HRD Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

Relapsed Ovarian Cancer Trial in Hangzhou (Secondary cytoreduction, Chemotherapy)

Recruiting
  • Relapsed Ovarian Cancer
  • Hangzhou, Zhejiang, China
    Women's Hospital, Zhejiang University School of Medicine
Nov 4, 2022

Ovarian Cancer, Carcinosarcoma Trial (Pamiparib)

Withdrawn
  • Ovarian Cancer
  • Carcinosarcoma
  • (no location specified)
Aug 3, 2021

Head and Neck Squamous Cell Carcinoma Trial in Brescia (Niraparib)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Brescia, Italy
    Asst Degli Spedali Civili Di Brescia
Aug 3, 2022

Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

Active, not recruiting
  • Fallopian Tube Endometrioid Tumor
  • +13 more
  • Orange, California
  • +19 more
Jan 10, 2023

Metastatic Pancreatic Cancer Trial in Lyon (Niraparib)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Lyon, France
    Centre Léon Bérard
Jul 4, 2022

Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

Not yet recruiting
  • Metastatic Solid Tumor
  • +4 more
  • San Francisco, California
    University of California, San Francisco
Jan 12, 2023

HRD Score in Chinese Ovarian Cancer Patients Benefiting From

Recruiting
  • Ovarian Cancer
    • Shanghai, Shanghai, China
      The Obstetrics and Gynecology Hospital of Fudan University
    Feb 24, 2022

    Ovarian Cancer Trial in Guangzhou (Pamiparib/Tamoxifen)

    Not yet recruiting
    • Ovarian Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Dec 30, 2022

    Pancytopenia Related to PARP Inhibitors (PancytoRIB)

    Completed
    • Cancer
    • PARP inhibitor
    • Caen, Basse Normandie, France
      Alexandre Joachim
    Sep 16, 2021

    Ovarian Cancer Trial in Madrid (Exercise and dietary recommendations)

    Not yet recruiting
    • Ovarian Cancer
    • Exercise and dietary recommendations
    • Madrid, Spain
    • +3 more
    Nov 15, 2023

    Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou

    Recruiting
    • Metastatic Castration-resistant Prostate Cancer
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Nov 1, 2021

      Homologous Recombination Deficiency in Chinese Ovarian Cancer

      Not yet recruiting
      • Ovarian Cancer
      • +2 more
      • PARP inhibitor
      • Nanjing, Jiangsu, China
        Xiaoxiang Chen, MD,PhD
      Sep 4, 2021

      Nasopharyngeal Carcinoma Trial in Brescia (Pembrolizumab)

      Recruiting
      • Nasopharyngeal Carcinoma
      • Brescia, Italy
        Asst Degli Spedali Civili Di Brescia
      Mar 29, 2022

      Pulmonary Toxicities Related to PARP Inhibitors (PulmonaRIB)

      Recruiting
      • Cancer
      • olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib
      • Caen, Basse Normandie, France
        Alexandre Joachim
      May 27, 2021

      Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer Trial in Baltimore (AG-01 Compound)

      Recruiting
      • Triple Negative Breast Cancer
      • +3 more
      • AG-01 Compound
      • Baltimore, Maryland
        University of Maryland Greenebaum Comprehensive Cancer Center
      Nov 16, 2022

      Head Neck Cancer Trial in New York ([18F]- PARPi, PET/CT Scans)

      Active, not recruiting
      • Head and Neck Cancer
      • [18F]- PARPi
      • PET/CT Scans
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Sep 14, 2021